Temozolomide and Capecitabine: An Effective Combination in Metastasic G2 NETs Abstract #709

Introduction: Treatment of neuroendocrine tumors (NETs) with chemotherapy has been validated in different studies. Recently a retrospective trial demonstrated high and durable response rate with Temozolomide and Capecitabine in 30 pancreatic NETs (pNETs).
Aim(s): To evaluate the efficacy and safety of this combination in metastatic G2 NETs.
Materials and methods: All patients with metastatic G2 NETs treated in our center with Temozolomide (150 mg/m2, days 10-14) and Capecitabine (1000 mg/m2 twice daily, days 1-14) every 28 days, both orally, from 25th October 2010 to 30th November 2012, were collected.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Chemotherapy
Presenting Author: María Jesús Barrio

To read results and conclusion, please login ...

Further abstracts you may be interested in

#449 Effective Treatment of a Metastatic Thymic Neuroendocrine Tumor with Capecitabine and Temozolomide: A Case Report
Introduction: Thymic neuroendocrine tumors are rare, with an estimated annual incidence of 0.2 per million. They are generally considered chemoresistant and there have been no reported cases of an objective response to therapy.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Vita SarangaPerry
#2136 Combination of Capecitabine and Temozolomide for Advanced Thymic Neuroendocrine Tumors
Introduction: In vitro data indicate that the combination of capecitabine(CAP) and temozolomide(TEM) is synergistic for induction of apoptosis in neuroendocrine tumor cell lines. It has been proven that the CAPTEM regimen is associated with an exceptionally high and durable response rate in patients with metastatic pancreatic neuroendocrine tumors. However, there is less evidence to illustrate if the CAPTEM regimen is effective for thymic neuroendorine tumors(TNET).
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Prof. Huang-Ying Tan
Authors: Wang X, Li Y L, Shi Y F, Chen Y Y, ...
#1356 Safety and Compliance of Capecitabine and Temozolomide in Patients with Advanced Neuroendocrine Tumours
Introduction: Capecitabine-temozolomide (CAPTEM) is a treatment option in patients (pts) with neuroendocrine tumours. Although efficacy data has been reported, no detailed safety information exists.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD, PhD Georgios Papaxoinis
#1611 A Study of S1/Temozolomide (STEM) Regimen in Patients with Metastatic Neuroendocrine Tumors
Introduction: Both single agent Capecitabine alone or Capecitabine in combination with Temozolomide have activity against neuroendocrine tumors (NETs), however, the role of S-1 in NETs is still unknown.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Chii Yihebali
Authors: Yihebali C, Jiuda Z, Yufeng W, Ba B, ...
#1389 Capecitabine and Temozolomide in NETs G1-2: The Experience of Various Hospitals in Spain
Introduction: Treatment of neuroendocrine tumors (NETs) with capecitabine-temozolomide (CAPTEM) is an option yet to be confirmed in phase III trials.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Guillermo Crespo Herrero